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Erythropoietic and non-erythropoietic functions of erythropoietin
(Epo) in mouse models
Abstract
As erythropoietin's (Epo) basic function is stimulation of red blood cell production, systemic
overexpression of Epo results in erythrocytosis. The patho-physiological consequences of chronically
elevated red blood cell counts have been studied in Epo overexpressing mice. Genetically modified
mice, however, played also an important role in discovering multiple additional functions of Epo besides
stimulating erythrocyte production. Non-erythropoietic functions of Epo are widespread and play a role
in organogenesis during early embryonic development and in tissue protection in ischemic diseases.
Future work in the field will most likely focus on these additional functions of Epo that harbor a great
clinical potential.
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Abstract 
As erythropoietin’s (Epo) basic function is stimulation of red blood cell production, 
systemic overexpression of Epo results in erythrocytosis. The patho-physiological 
consequences of chronically elevated red blood cell counts have been studied in Epo 
overexpressing mice. Genetically modified mice, however, played also an important role 
in discovering multiple additional functions of Epo besides stimulating erythrocyte 
production. Non-erythropoietic functions of Epo are widespread and play a role in 
organogenesis during early embryonic development and in tissue protection in ischemic 
diseases. Future work in the field will most likely focus on these additional functions of 
Epo that harbor a great clinical potential. 
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Detailed phenotyping of experimentally mutated mice are helpful in understanding 
physiology. Thus, it was a milestone in understanding biological processes and the 
multiple interactions between the different organ systems of the mammalian organism 
when genetically modified mice became available for research. This era started 1977 
with the first transgenic mouse (Jaenisch, 1977) and the refinement of this technique a 
few years later (Palmiter & Brinster, 1985). Finally, the discoveries of how 
homologous recombination between segments of DNA molecules can be used to 
specifically target genes in the mammalian genome has been honored by the 2007 
Nobel Prize in physiology or medicine to Drs Mario R. Capecchi, Martin J. Evans and 
Oliver Smithies. In this review we will summarize the insights into the biology of 
erythropoietin (Epo) gained from the investigation of genetically modified mice 
regarding Epo or its receptor (EpoR). 
 
Epo-trangenic mice  
The first Epo-transgenic mouse line harboring the full-length human Epo gene was 
published 1989 (Semenza et al., 1989), and was followed up by additional ones from the 
same group (Semenza et al., 1991). These mouse lines were used to study the 
mechanisms resulting in tissue specific expression of Epo in liver and kidney. In 
analogy, another group generated several different Epo-transgenic mouse lines in order 
to study the effects of various amounts of flanking DNA on Epo gene expression 
(Madan et al., 1995). The next Epo-transgenic mouse model published (Ruschitzka et 
al., 2000) was generated to assess the cardio-vascular effects of excessive erythrocytosis. 
Most recently, a transgenic mouse line expressing the human Epo cDNA under the 
control of the bovine beta-casein promotor has been generated but only one out of five 
founding lines survived exhibiting moderate erythrocytosis with a hematocrit of 63% 
(Kim et al., 2007). Especially the so-called tg6 mouse line generated by Ruschitzka et al. 
(Ruschitzka et al., 2000) has been used extensively to study the patophysiology of 
excessive erythrocytosis but in the past decades it turned out that Epo has many other 
functions apart from promoting red cell production.  
 
Non-erythropoietic functions of Epo  
In addition to the studies on the patho-physiological consequences of excessive 
erythrocytosis, other genetically modified mouse lines have revealed important 
insights to Epo’s additional biological effects that were independent on the production 
of red cells (table 1). This started with studies on mice lacking either Epo or its 
receptor (EpoR) (Wu et al., 1999). Mice deficient for Epo or EpoR die around 
embryonic day 13.5 only partly due to impaired erythropoiesis. In the developing 
mouse heart EpoR is expressed between embryonic day 10.5 and 14.5. The loss of 
Epo signaling in the embryonic heart results in severe ventricular hypoplasia 
independent of hypoxia due to a reduction in the number of proliferating cardiac 
myocytes as well as epicardium detachment and abnormalities in the vascular network 
(Wu et al., 1999).  
Epo signaling might also play a role in the development of the central nervous system. 
Different experiments analyzing binding of 125I-labeled Epo, EpoR mRNA levels as 
well as the expression of lacZ under control of the EpoR promotor have revealed that 
EpoR is highly expressed in the embryonic brain and also to a lesser extend in the 
adult central nervous system (Digicaylioglu et al., 1995; Marti et al., 1996; Liu et al., 
1997; Chen et al., 2006). In addition, progenitor cells from endothelial and skeletal 
muscle show EpoR expression (Anagnostou et al., 1994; Ogilvie et al., 2000). In this 
context it is interesting that lethality of EpoR deficiency can be rescued by EpoR 
expression restricted to erythroid cells, resulting in mice without obvious phenotype 
(Suzuki et al., 2002). This finding indicates that further studies are necessary to define 
the function of Epo in normal embryonic development. In adulthood, however, the 
lack of EpoR in non-hematopoietic tissues might be a disadvantage in disease 
situations, as has been demonstrated by rescuing EpoR deficient mice (Suzuki et al., 
2002) for pulmonary hypertension (Satoh et al., 2006). In line with these findings, tg6 
mice that chronically overexpress the human Epo gene do not develop pulmonary 
hypertension in normoxia or after exposure to chronic hypoxia (10% O2 for 3 weeks) 
(Weissmann et al., 2005). 
Despite the fact that the EpoR is massively (4 orders of magnitude) down-regulated in 
neuronal tissues until embryonic day 17 (Liu et al., 1994) there is considerably 
evidence that Epo is functional in the adult brain. For example, acclimatization to a 
hypoxic environmant involves carotid body stimulation by peripherally produced Epo 
as well as Epo up-regulation in combination with down-regulation of the soluble 
EpoR in central respiratory centers of the brain stem (Soliz et al., 2005; Soliz et al., 
2007). Of great clinical importance is that Epo is supposed to have protective 
functions in many different tissues (Sasaki et al., 2001). In the brain, both Epo and its 
receptor are up-regulated during ischemia/hypoxia (Sakanaka et al., 1998; Siren et al., 
2001b) and Epo administration considerably inhibits apoptosis after middle cerebral 
artery occlusion (Siren et al., 2001a). These findings resulted in a clinical study in 
stroke patients confirming the beneficial effects of Epo therapy in case of brain 
ischemia (Ehrenreich et al., 2002) but only in patients not additionally receiving 
recombinant tissue plasminogen activator (Ehrenreich et al., 2009). In line with this, 
in mice overexpressing Epo solely in the brain (termed tg21) infarct volume was 
about 22% but not significantly lower compared to wild type controls (Wiessner et 
al., 2001). In contrast, the same study showed that mice systemically overexpressing 
Epo with hematocrit values around 0.85 (tg6) had 49% enlarged infarct volumes 
suggesting that increased hematocrit levels and/or the concomitantly elevated serum 
NO levels might deteriorate possible protective effects of Epo after stroke. Apart from 
its positive effects in acute ischemic brain damage, Epo was also shown to be 
beneficial for treatment of blunt cortical trauma, neurotoxin exposure and 
experimental autoimmune encephalitis (model of multiple sclerosis) (Brines et al., 
2000). In keeping with neuronal tissue, the mouse retina is protected the against light-
induced degeneration by inhibiting photoreceptor cell apoptosis by Epo, either 
induced by hypoxic preconditioning or direct application of recombinant human Epo 
(Grimm et al., 2002). Similarly, Epo overexpression in the retina as it occurs in tg6 
mice protects against light-induced retinal degeneration (Grimm et al., 2004). 
Photoreceptor apoptosis is also the common path in retinitis pigmentosa (RP). 
Crossbreeding with two mouse models of human RP with tg6 mice however did not 
affect the time course or the extent of retinal degeneration in a light-independent (rd1) 
and a light-accelerated (VPP) mouse model of RP. Similarly, repetitive intraperitoneal 
injections of recombinant human Epo did not protect the retina in the rd1 and the VPP 
mouse. These effects were not due to adaptational downregulation of Epo receptor 
(Grimm et al., 2004). Thus, Epo appears to be protective in the retina during acute, 
light-induced photoreceptor cell death but not in genetically based retinal 
degeneration. 
Apart from its beneficial effects under pathological conditions Epo appears to 
modulate cognitive function. This effect can at least partly explained by changes in 
hematocrit (Weiskopf et al., 2006) but there is most likely an additional effect of Epo 
directly in the brain. In contrast to brain ischemia in healthy mice systemically 
administered Epo needs to cross the blood brain barrier to exert effects on neurons. 
Indeed, it was suggeasted that that 0.5 to 1% of a systemically administered high Epo 
dosage crosses undamaged the blood brain barrier, according to the authors, by 
receptor mediated transcytosis (Brines et al., 2000; Brines & Cerami, 2005). Intra-
peritoneal injections of Epo in healthy wild type mice improved sequential learning 
and memory components of a complex long-term cognitive task (El-Kordi et al., 
2009). This can be explained by modulating plasticity, synaptic connectivity and 
activity of memory-related neuronal networks in the hippocampus (Adamcio et al., 
2008). Effects of Epo in brain tissue of healthy mice require Epo’s capability to cross 
the intact blood brain barrier. As Epo is a large molecule (molecular weight: 34kD) 
this appears to be quite unlikely and consequently has been questioned (Boado et al., 
2010).  
Similar as for ischemic neuronal tissue Epo has tissue protective effects also in other 
tissues suggesting a stereotypic mechanism, maybe with the endothelial cells as a key 
player in this process. Indeed, the endothelium was the first non-hematopoietic tissue 
described as a physiological target for Epo (Knudtzon & Mortensen, 1975). Later it 
was established that Epo is a growth and chemotactic factor for endothelial cells 
(Anagnostou et al., 1990). Moreover tissue repair appear to be at least supported by 
Epo-induced release of endothelial progenitor cells from the bone marrow (Heeschen 
et al., 2003; Westenbrink et al., 2007; Santhanam et al., 2008). Numerous studies 
show also the expression of Epo-receptors on other than endothelial cells (Noguchi et 
al., 2008). For example in the ischemic heart this effect appears to rely on direct 
protective effects on cardiomyocytes and endothelial cells as well as stimulation of 
angiogenesis (Ruifrok et al., 2008). Another example is the protective effect of 
stimulation of non-erythropoietic Epo receptors observed in a murine kidney 
ischemia-reperfusion model (Brines et al., 2008). The protective properties of Epo 
might rest on a counterbalancing effect of Epo against tumor necrosis factor α 
(TNFα) that ultimately results in increased apoptosis of cell that escaped the initial 
tissue damage (Brines, 2010). In addition, Epo appears to promote tissue repair by 
supporting or inducing angiogenesis. Mice studies revealed that the transcription 
factor sonic hedgehog could play a role in promoting the pro-angionetic effects of 
Epo in the post-ischemic heart (Ueda et al., 2010).  
The non-erythropoietic functions of Epo might be transduced by a receptor distinct of 
that found on erythroid cells. Interestingly it could be shown that on erythroid cells 
interleucine 3 (IL3) also is able to stimulate hemoglobine synthesis (DiFalco & 
Congote, 2002). While on erythroid cells the EpoR is a homodimer of two identical 
subunits (Jelkmann et al., 2008) whereas the IL3 receptor is a heteridimer consisting 
of an α-subunit with high affinity to IL3 and the common βc-subunit. It has been 
speculated that in extra-hematopoietic tissues the Epo receptor is a heterodimer 
between one Epo receptor monomer and the common βc-subunit that is shared by the 
IL3, IL5 and GM-CSF receptors (Leist et al., 2004; Brines & Cerami, 2006). These 
distinct Epo receptors could represent the physiological basis for development of 
tissue protective Epo analogons that have no unwanted effects on hematopoiesis. 
Taken together there is overwhelming data showing that Epo has many non-
erythropoietic functions. As such, it appears arduous that some authors still claim that 
the EpoR has no further biological function apart from erythropoiesis (Sinclair et al., 
2010; Swift et al., 2010) but this statement has been clearly refuted (Ghezzi et al., 
2010). 
 
Conclusion and outlook  
In summary, genetically modified mice taught us that Epo has several non-
hematopoietic functions. This was a clinically very important discovery and will 
surely be the future direction of the research in the field. Thus, many new details 
about these additional functions of Epo will be discovered as expression of Epo, and 
its receptor, has been shown in numerous tissues including the reproductive organs, 
gastric mucosal cells, pancreatic islets, inner ear and prostate epithelial cells. The 
exact mechanisms for the non-erythropoietic functions of Epo await further 
elucidation but there are efforts to develop drugs that specifically stimulate Epo 
receptors in non- erythropoietic tissues thus avoiding the negative side effects of 
increased hematocrit values (Ueba et al., 2010). The rationale behind these efforts is 
based on the fact the EpoR in non-erythopoietic tissues might differ from that 
transducing erythropoiesis (Masuda et al., 1993). Accordingly, using peptide 
analogues of the B-helix of the 4 α-helices (A-D) containing Epo molecule were 
successfully used to induce tissue protection without increasing hematocrit (Leist et 
al., 2004; Brines et al., 2008). One day these peptides might be replaced by small, 
orally active non-erythopoietic Epo receptor mimetics. 
 
Mouse model main finding reference 
Epo-/- or EpoR-/- Embryonically lethal due to anemia 
and heart hypoplasia. 
(Wu et al., 1999) 
EpoR-tg or 
EpoR-LacZ-tg 
EpoR is highly expressed in the 
embryonic brain. 
(Liu et al., 1997) 
Brain restricted 
Epo-tg (tg21) 
Brain-derived Epo (brain stem) 
regulates the hypoxic ventilatory 
response 
(Soliz et al., 2005) 
tg6 and tg21 Epo is protective in cerebral 
infarction as long as the hematocrit is 
normal 
(Wiessner et al., 2001) 
tg6 Systemic Epo is protective in 
hypoxia induced pulmonary 
hypertension 
(Weissmann et al., 2005) 
tg6, rd1 & VPP Epo is protective in light-induced 
photoreceptor apoptosis but not 
retinitis pigmentosa 




Cardio protective effects of Epo in 
heart ischemia require sonic 
hedgehog signaling 
(Ueda et al., 2010) 
 
Table 1: Some non-erythropoietic functions of Epo as discovered using genetically 
modified mice. Additional non-erythropoietic Epo functions have been established 
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